Table 1.

Multiplex analysis of soluble factors secreted by M102 cell line after chemotherapeutic drug treatment

AnalyteMean ± SD (pg/mL; temozolomide)Mean ± SD (pg/mL; DMSO)Fold increasePMean ± SD (pg/mL; cisplatin)Mean ± SD (pg/mL; DMF)Fold increaseP
b-NGFNDNDNANANDNDNANA
CTACKNDNDNANANDNDNANA
Eotaxin42.1 ± 16.497.3 ± 89.80.430.2584.5 ± 101119.3 ± 133.60.710.35
FGF basic41.5 ± 12.722.3 ± 18.71.860.1044.8 ± 16.742.9 ± 451.040.35
G-CSFNDNDNANANDNDNANA
GM-CSF100.1 ± 73.875 ± 81.51.330.2058.5 ± 58.7124.6 ± 166.80.470.50
GROα3,776 ± 977.81,009 ± 377.13.740.05309.8 ± 87.4293.9 ± 198.71.050.35
HGFNDNDNANANDNDNANA
IFN-α2NDNDNANANDNDNANA
IFNγ254 ± 199.3319.6 ± 276.40.790.3583.1 ± 42.4700.5 ± 776.80.120.10
IL-1αNDNDNANANDNDNANA
IL-1βNDNDNANANDNDNANA
IL-1ra200.2 ± 162.1221.4 ± 184.10.90.41131.3 ± 118.1298 ± 256.40.460.35
IL-2NDNDNANANDNDNANA
IL-2raNDNDNANANDNDNANA
IL-3NDNDNANANDNDNANA
IL-4NDNDNANANDNDNANA
IL-5NDNDNANANDNDNANA
IL-6NDNDNANANDNDNANA
IL-7NDNDNANANDNDNANA
IL-8/CXCL883,229 ± 67,8107,869 ± 2,35410.580.0511,343 ± 1,8562,144 ± 1,2435.290.05
IL-975.3 ± 50.971.5 ± 55.50.920.5010.2 ± 1.5113 ± 117.10.090.05
IL-1019.4 ± 16.248.1 ± 29.40.40.1010.3 ± 765.8 ± 710.160.10
IL-12p40NDNDNANANDNDNANA
IL-12p7088 ± 87.891.6 ± 77.61.130.4123.4 ± 19.4143.6 ± 162.10.160.10
IL-13NDNDNANANDNDNANA
IL-15NDNDNANANDNDNANA
IL-1640.8 ± 34.756.1 ± 62.30.730.5041.8 ± 35.1103 ± 123.30.410.35
IL-17103.8 ± 97130.1 ± 147.40.80.50114.4 ± 125.8125.6 ± 109.80.910.50
IL-18NDNDNANANDNDNANA
IP-10/CXCL103,810 ± 1,122268.7 ± 268.814.180.05667.3 ± 215.3115.8 ± 100.25.760.05
LIF13,478 ± 11,8436,288 ± 5,5082.140.25188.1 ± 16.42,258 ± 383.40.080.05
MCP-1/CCL2522.8 ± 46.85.3 ± 1.698.290.04NDNDNANA
MCP-3/CCL7NDNDNANANDNDNANA
M-CSF86.7 ± 75.730.7 ± 35.72.920.17121.4 ± 103.627.7 ± 30.54.380.17
MIF6,475 ± 522.8246.7 ± 54.926.250.0513,356 ± 3,597874.3 ± 236.815.280.05
MIG/CXCL947 ± 1.45.1 ± 5.19.170.05NDNDNANA
MIP-1α/CCL3NDNDNANANDNDNANA
MIP-1β/CCL4NDNDNANANDNDNANA
PDGF-bb65.7 ± 44.157 ± 671.150.3522.9 ± 14.493.3 ± 82.60.250.10
RANTES/CCL5330.4 ± 12.128.7 ± 11.611.50.0529 ± 10.427.3 ± 22.71.060.35
SCF40.6 ± 35.644.4 ± 40.10.910.5077.2 ± 66.920 ± 28.23.870.27
SCGF-β1,025 ± 405.71,290 ± 431.50.790.20832.9 ± 226.92,916 ± 2,7900.290.05
SDF-1αNDNDNANANDNDNANA
TNF-αNDNDNANANDNDNANA
TNF-βNDNDNANANDNDNANA
TRAILNDNDNANANDNDNANA
VEGF36,847 ± 6,11744,477 ± 33,9650.830.3516,688 ± 5,20655,394 ± 46,3100.30.35

NOTE: Human melanoma cell line M102 was cultured with temozolomide (100 μg/mL) or cisplatin (10 μg/mL) for 3 days. Supernatants were collected and the concentrations of various soluble factors were analyzed using xMAP multiplex technology. Data show the production of cytokines, chemokines, angiogenic, and growth factors in pg/mL ± SD from the supernatant of drug-treated cells compared with control cells. Results are representative of 3 independent samples analyzed. Secreted factors that are significantly upregulated after drug treatment are indicated in bold.

Abbreviations: ND, not detected; NA, not available. Mann–Whiney U test, 1-tailed.